In recent years, there has been a colossal national push by both the Australian public and the medical industry for the Australian government to recognise and support the numerous medical benefits offered by medicinal cannabis therapy.

It is claimed that medicinal cannabis can decrease anxiety, provide relief from chronic pain, alleviate nausea, assist symptoms of spasticity in people with multiple sclerosis and treat epilepsy. With this number and breadth of benefits, it is easy to see why many Australians pushed for a law reform to relax Australia’s historically tight laws surrounding access, cultivation and prescription of medicinal cannabis.

Recognition by the Australian government of the public interest in medicinal cannabis was first seen in November 2014 when a cross party Bill titled the Regulator of Medicinal Cannabis Bill 2014 (“the 2014 Bill”), was introduced to Parliament. The 2014 Bill was referred to the Senate Legal and Constitutional Affairs Legislation Committee in February 2015 and a report addressing the subject was produced in August 2015. The report raised a number of structural issues and the Bill finally lapsed at prorogation on 17 April 2016. One particular complication was Australia’s international obligation and agreement to comply with the United Nations Single Convention on Nacrotic Drugs 1961.

All was not lost however as on 10 February 2016 the Australian Government introduced a new Bill titled the Narcotic Drugs Amendment Bill 2016 (“the 2016 Bill”) which addressed the concerns tabled in the August 2015 report while ensuring Australia remained compliant with its international obligations. The 2016 Bill aimed to enable the cultivation of medicinal cannabis in Australia and improve access to the therapeutic drug for patients in need. In a milestone moment, the 2016 Bill was passed on 24 February 2016.

Medicinal cannabis contains a group of chemical compounds known as cannabinoids. One of those compounds is cannabidiol, more commonly known as CDB. From 1 June 2015 the TGA announced that medicinal cannabis CBD products containing less than 2% of the other cannabinoids found in cannabis are to be scheduled as Schedule 4 Prescription Only medicines in the Poisons Standard.

Another leap was made by the Therapeutic Goods Administration (TGA) department of the Australian Government Department of Health. The TGA is the Australian government body responsible for the regulation of all therapeutic goods in Australia, including controlling the import, export, supply, manufacture of and advertisement of all therapeutic goods. On 1 November 2016 the TGA made the significant decision to downgrade the scheduling of certain medicinal cannabis products in the Poisons Standard from Schedule 9 prohibited substances to Schedule 8 controlled drugs. This decision opened the door for patient access to a much wider range of medicinal cannabis products.

These key changes in legislation and scheduling by the Australian government enabled, for the first time, certain medicinal cannabis products to be registered on the Australian Register of Therapeutic Goods (ARTG) and thus become ‘approved’ products.

Today, in 2019, medicinal cannabis products are still tightly controlled therapeutic goods which are highly regulated through a complex maze of both Commonwealth and State/Territory laws. While recreational cannabis remains illegal nationally, it is now possible for medicinal cannabis products to be accessed and prescribed to patients in need on a case-by-case basis. On 19 February 2019 the Australian Broadcasting Corporation (“ABC”) revealed that more than 3,100 medicinal cannabis scripts had been approved by the TGA. While this is clearly a step in the right direction, experts estimate that as many as 100,000 Australians continue self-medicate with illegal cannabis due to the numerous hurdles which still need to be crossed to access approved medicinal cannabis.

We can only hope that the numerous milestones we have achieved as a Nation in the past few years with regard to medicinal cannabis continue into the near future to enable all patients in need to benefit from the medication.


For more information, please contact a member of our Start Ups and Emerging Enterprises Team.

Related Articles

View All
Commercial Contracts & Agreements / Employment Law / Litigation & Dispute Resolution

New Limitations On Fixed Term Employment Contracts – Employers need to know what they don’t know!

As of today (6 December 2023), there will be new rules that impact the use of fixed term employment contracts These are...
Read More
Leasing & Lease Disputes / Real Estate Agents / Small to Medium Enterprises

Is your retail tenant continuously in breach of your retail lease but still wants to renew the lease for another term?

A tenant can be in breach of a lease in a multitude of ways depending on each lease, be it late rent and outgoings...
Read More
Commercial Law / Employment Law / Litigation & Dispute Resolution

International Women’s Day 2023: Embrace Equity

Have you ever wondered why the hallmark colours of International Women’s Day are vibrant purple, bold green and stark...
Read More
Commercial Law / Commercial Contracts & Agreements / Start-ups & Emerging Enterprises

Frustration, Force Majeure & Risk: Lessons for Business in Uncertain Times

Why is a force majeure clause so important A “force majeure” clause is a provision addressing the parties’ rights...
Read More
Commercial Contracts & Agreements / Franchising & Licensing / Start-ups & Emerging Enterprises

Recording: TLFC Law Lunchtime Briefing: Internal Business Disputes

Chaired By Michael Fetter, Principal, and presented by Rob Oxley, Principal, Felicity Simpson, Special Counsel and...
Read More
Commercial Contracts & Agreements / Small to Medium Enterprises / Start-ups & Emerging Enterprises

Best mates starting a company – what could go wrong?

What is a Shareholders Agreement A Shareholders Agreement is a document which sets out the ongoing relationship between...
Read More
Commercial Law / Commercial Contracts & Agreements / Corporate Advisory and M&A

Announcing our Promotions

Rob joined us in 2017 and immediately impressed us with his litigation skills and incredible work ethic It’s no...
Read More
Employment Law / Small to Medium Enterprises / Start-ups & Emerging Enterprises

Fair Work Commission amends 99 Awards during COVID-19 Pandemic

On Wednesday, 8 April 2020, as a result of the COVID-19 Pandemic, a six (6) member Fair Work Commission full bench,...
Read More
Construction / Construction / Developments

TLFC Law’s Blog Highlights for 2019

Read on for our 2019 blog highlights The Sun Sets on Developer Rights PROPERTY LAW Following lengthy discussions in...
Read More
Start-ups & Emerging Enterprises / International Investors

Capital Raising: 5 Key Tips from the Minds of Lawyers, Entrepreneurs and Investors

Given the rapid growth of technological and entrepreneurial advancements around the globe, the right head-start...
Read More
Information Technology & Innovation / Start-ups & Emerging Enterprises

Faking It: The Latest Threat to your Identity

But what if the dread of such embarrassing content lingered beyond milestone celebrations What if embarrassing videos...
Read More
Commercial Law / Commercial Contracts & Agreements / Corporate Advisory and M&A

Negotiating Indemnities: Some Practical Tips

An appropriate indemnity can provide a valuable mechanism for risk allocation between parties to commercial dealings...
Read More